{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:06:38Z","timestamp":1785769598147,"version":"3.56.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Malignant Adnexal Tumors of the Skin (MATS) are rare neoplasms that differentiate into adnexal structures, including hair follicles, sebaceous glands, and eccrine or apocrine glands. With an incidence of approximately 5 per 1 million person-years, there are no standardized guidelines for their diagnosis and treatment, leading to inconsistent outcomes. This study aims to describe the clinicopathological characteristics and outcomes in an oncology reference center over 15 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods:<\/jats:title>\n                    <jats:p>We retrospective analyzed 40 patients diagnosed with MATS at the National Cancer Institute of Mexico from 2005 to 2020. We collected clinical variables (age, gender, histological subtype, tumor site, and treatment) and pathological features (tumor size, lymphovascular invasion, perineural invasion, depth, necrosis, and margin status). We analyzed disease-free survival (DFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age at diagnosis was 64 years, with a slight male predominance (55 %). Eccrine\/apocrine tumors were the most common (57.5 %), followed by sebaceous (25 %) and follicular tumors (17.5 %). The head and neck were the most frequent sites (52.5 %). Surgical excision was performed in 95 % of patients, with adjuvant radiotherapy in 17.5 %. Lymph node metastases were present in 5 %, and no distant metastases were observed initially. Recurrence occurred in 17.5 % of patients. Median DFS was 45.3 months, and median OS was 48.9 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Radical excision remains the primary treatment for MATS, though adjuvant radiotherapy may be helpful in high-risk cases. Prospective studies are needed to establish treatment guidelines and to improve outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2025.111852","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:12:03Z","timestamp":1756192323000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Malignant adnexal skin tumors: A 15-year case series analysis from a Latin-American institution"],"prefix":"10.1097","volume":"135","author":[{"given":"Ana Paulina","family":"Mel\u00e9ndez-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Skin and Soft Tissue Tumors Department, National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"S\u00e1nchez-Serv\u00edn","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian Yarih","family":"Garc\u00eda-Ortega","sequence":"additional","affiliation":[{"name":"Skin and Soft Tissue Tumors Department, National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Teresa","family":"Vega-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Skin and Soft Tissue Tumors Department, National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia H.","family":"Caro-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Mart\u00ednez-Said","sequence":"additional","affiliation":[{"name":"Skin and Soft Tissue Tumors Department, National Cancer Institute, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"4","key":"R1-49-20260803","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040998","article-title":"Treatment of malignant adnexal tumors of the skin: a 12-year perspective","volume":"14","author":"Kleibert","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"R2-49-20260803","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-018-1401-y","article-title":"Malignant adnexal tumors of the skin: a single institution experience","volume":"16","author":"Oyasiji","year":"2018","journal-title":"World J. Surg. Oncol"},{"issue":"6","key":"R3-49-20260803","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archdermatol.2010.105","article-title":"Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study","volume":"146","author":"Blake","year":"2010","journal-title":"Arch. Dermatol"},{"issue":"9","key":"R5-49-20260803","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/archdermatol.2011.229","article-title":"Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors","volume":"147","author":"Martinez","year":"2011","journal-title":"Arch. Dermatol"},{"key":"R6-49-20260803","article-title":"Revised Preferred Reporting of Case Series in Surgery (PROCESS) guideline: an update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Premier Journal of Science"},{"key":"R7-49-20260803","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/ijd.12448","article-title":"Poroma: a review of eccrine, apocrine, and malignant forms","volume":"53","author":"Sawaya","year":"2014","journal-title":"Int. J. Dermatol"},{"issue":"1","key":"R8-49-20260803","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/ijd.ijd_838_21","article-title":"Rare tumors of the skin: malignant cutaneous adnexal tumors and clinicopathological features","volume":"68","author":"Melekber","year":"2023","journal-title":"Indian J. Dermatol"},{"key":"R10-49-20260803","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/S1470-2045(19)30673-4","article-title":"Sebaceous carcinoma: evidence-based clinical practice guidelines","volume":"20","author":"Owen","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"R11-49-20260803","first-page":"5263","article-title":"Chemotherapy of rare skin adnexal tumors: a review of literature","volume":"34","author":"De Iuliis","year":"2014","journal-title":"Anticancer Res"},{"key":"R12-49-20260803","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jso.23331","article-title":"Increasing incidence and survival of a rare skin cancer in the Netherlands. A population-based study of 2,220 cases of skin adnexal carcinoma","volume":"107","author":"Stam","year":"2013","journal-title":"J. Surg. Oncol"},{"key":"R13-49-20260803","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s10147-013-0594-x","article-title":"Treatment strategy for cutaneous apocrine carcinoma","volume":"19","author":"Ogata","year":"2014","journal-title":"Int. J. Clin. Oncol"},{"key":"R14-49-20260803","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/cup.13046","article-title":"Pilomatrix carcinoma: 12-year experience and review of the literature","volume":"45","author":"Jones","year":"2018","journal-title":"J. Cutan. Pathol"},{"key":"R15-49-20260803","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1078272","article-title":"Systematic analysis and case series of the diagnosis and management of trichilemmal carcinoma","volume":"12","author":"Sun","year":"2023","journal-title":"Front. Oncol"},{"key":"R16-49-20260803","doi-asserted-by":"crossref","first-page":"356","DOI":"10.15761\/GOD.1000188","article-title":"Treatment of primary cutaneous apocrine carcinoma of the scalp\u2014case and review of the literature","volume":"3","author":"Brown","year":"2016","journal-title":"Glob. Dermatol"},{"key":"R17-49-20260803","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1468-3083.2009.03301.x","article-title":"Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma","volume":"24","author":"Battistella","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol"},{"key":"R18-49-20260803","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-018-0357-3","article-title":"Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma","volume":"6","author":"Domingo-Musibay","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"R19-49-20260803","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/IOP.0000000000001164","article-title":"Carboplatin and pembrolizumab chemoimmunotherapy achieves remission in recurrent, metastatic sebaceous carcinoma","volume":"34","author":"Kodali","year":"2018","journal-title":"Ophthalmic Plast. Reconstr. Surg"},{"key":"R20-49-20260803","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS219","article-title":"A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057)","volume":"36","author":"Silk","year":"2018","journal-title":"JCO"},{"issue":"12","key":"R21-49-20260803","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00066-006-1600-2","article-title":"Pilomatrix carcinoma with lymph node and pulmonary metastases","volume":"182","author":"Tselis","year":"2006","journal-title":"Strahlenther. Onkol"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261225010387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261225010387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijscr.2025.111852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:14:46Z","timestamp":1785766486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijscr.2025.111852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2025.111852","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}